HomeCompareCYBN vs MO

CYBN vs MO: Dividend Comparison 2026

CYBN yields 24.15% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYBN wins by $16.2K in total portfolio value
10 years
CYBN
CYBN
● Live price
24.15%
Share price
$8.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$93.9K
Annual income
$10,269.79
Full CYBN calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — CYBN vs MO

📍 CYBN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYBNMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYBN + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYBN pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYBN
Annual income on $10K today (after 15% tax)
$2,053.14/yr
After 10yr DRIP, annual income (after tax)
$8,729.32/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MO beats the other by $15,893.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYBN + MO for your $10,000?

CYBN: 50%MO: 50%
100% MO50/50100% CYBN
Portfolio after 10yr
$85.8K
Annual income
$19,619.16/yr
Blended yield
22.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

CYBN
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
4.3
Piotroski
0/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYBN buys
0
MO buys
11
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MO▲ Buy$1,000 - $15,0002025-08-04
Sheri Biggs🏢 House$MO▼ Sell$1,001 - $15,0002025-03-19
Pete Sessions🏢 House$MO▼ Sell$1,001 - $15,0002024-09-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-03-20
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-02-13
Virginia Foxx🏢 House$MO▼ Sell$1,001 - $15,0002024-01-16
Virginia Foxx🏢 House$MO▲ Buy$1,001 - $15,0002024-01-11
Ro Khanna🏢 House$MO▼ Sell$1,001 - $15,0002024-01-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-01-10
Virginia Foxx🏢 House$MO▼ Sell$15,001 - $50,0002024-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYBNMO
Forward yield24.15%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$93.9K$77.7K
Annual income after 10y$10,269.79$28,968.54
Total dividends collected$58.5K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: CYBN vs MO ($10,000, DRIP)

YearCYBN PortfolioCYBN Income/yrMO PortfolioMO Income/yrGap
1← crossover$13,115$2,415.46$10,558$768.31+$2.6KCYBN
2$16,994$2,960.73$11,352$1,015.87+$5.6KCYBN
3$21,769$3,585.38$12,482$1,367.86+$9.3KCYBN
4$27,585$4,292.32$14,103$1,883.39+$13.5KCYBN
5$34,600$5,083.28$16,472$2,664.91+$18.1KCYBN
6$42,980$5,958.72$20,024$3,897.79+$23.0KCYBN
7$52,907$6,917.79$25,537$5,933.74+$27.4KCYBN
8$64,569$7,958.38$34,478$9,476.77+$30.1KCYBN
9$78,166$9,077.18$49,776$16,022.63+$28.4KCYBN
10$93,907$10,269.79$77,699$28,968.54+$16.2KCYBN

CYBN vs MO: Complete Analysis 2026

CYBNStock

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Full CYBN Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this CYBN vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYBN vs SCHDCYBN vs JEPICYBN vs OCYBN vs KOCYBN vs MAINCYBN vs PMCYBN vs BTICYBN vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.